BE2013C032I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C032I2
BE2013C032I2 BE2013C032C BE2013C032C BE2013C032I2 BE 2013C032 I2 BE2013C032 I2 BE 2013C032I2 BE 2013C032 C BE2013C032 C BE 2013C032C BE 2013C032 C BE2013C032 C BE 2013C032C BE 2013C032 I2 BE2013C032 I2 BE 2013C032I2
Authority
BE
Belgium
Prior art keywords
disorders
constipation
conditions
dyspepsia
functional
Prior art date
Application number
BE2013C032C
Other languages
Dutch (nl)
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of BE2013C032I2 publication Critical patent/BE2013C032I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)

Abstract

The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
BE2013C032C 2003-01-28 2013-05-24 BE2013C032I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12

Publications (1)

Publication Number Publication Date
BE2013C032I2 true BE2013C032I2 (en) 2023-08-22

Family

ID=32854294

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C032C BE2013C032I2 (en) 2003-01-28 2013-05-24

Country Status (28)

Country Link
US (3) US20040266989A1 (en)
EP (3) EP1594517B1 (en)
JP (3) JP4584911B2 (en)
KR (2) KR101227626B1 (en)
CN (2) CN100589839C (en)
AT (2) ATE477268T1 (en)
AU (2) AU2004210161B2 (en)
BE (1) BE2013C032I2 (en)
BR (2) BR122018074353B8 (en)
CA (1) CA2514507C (en)
CY (5) CY1110905T1 (en)
DE (2) DE602004007105T2 (en)
DK (3) DK1911763T3 (en)
ES (3) ES2387848T3 (en)
FR (2) FR13C0029I2 (en)
HU (1) HUS1300022I1 (en)
IL (2) IL169863A (en)
LT (1) LTC1594517I2 (en)
LU (2) LU92200I2 (en)
MX (1) MXPA05008097A (en)
NL (1) NL300593I2 (en)
NO (3) NO334112B1 (en)
NZ (2) NZ570134A (en)
PT (3) PT1911763E (en)
RU (2) RU2353383C2 (en)
SG (2) SG192300A1 (en)
SI (3) SI2246360T1 (en)
WO (1) WO2004069165A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4206272B2 (en) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド Guanylate cyclase receptor agonists for treating tissue inflammation and carcinogenesis
ATE477268T1 (en) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
WO2005115412A2 (en) * 2004-05-25 2005-12-08 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
JPWO2006046746A1 (en) * 2004-10-26 2008-05-22 味の素株式会社 Visceral pain prevention / treatment agent
WO2007022531A2 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN105381453B9 (en) 2005-09-29 2019-01-11 益普生制药股份有限公司 Compositions and methods for stimulating gastrointestinal motility
EP1996218A4 (en) * 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
EP2650303A1 (en) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
RU2009144972A (en) * 2007-05-04 2011-06-10 Айронвуд Фармасьютикалз, Инк. (Us) COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH DELAY OF SALT OR LIQUID
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005515A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Protein expression methods
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20120213846A1 (en) * 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
CA2743172A1 (en) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
AU2009322285B2 (en) * 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
WO2010115916A1 (en) 2009-04-10 2010-10-14 F. Hoffmann-La Roche Ag Process for isolating therapeutic peptide
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
PH12012500916B1 (en) 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EP2509992B1 (en) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2011156453A2 (en) 2010-06-09 2011-12-15 Combimab, Inc. Therapeutic peptides
HRP20192207T1 (en) 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc PREPARATIONS OF GUANYLATE CYCLASE-C AGONISTS AND METHODS OF USE
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatment of gastrointestinal disorders
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
RU2528641C2 (en) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Method of treating patients with dyspepsia syndrome combined with overweight
CN102875655B (en) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 Linaclotide synthesis method
EP2950803A1 (en) 2013-01-30 2015-12-09 Sandoz AG Crystalline form of linaclotide
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
KR20160042039A (en) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 Compounds and methods for inhibiting phosphate transport
HUE061954T2 (en) * 2015-05-01 2023-09-28 Ironwood Pharmaceuticals Inc Compositions for colon cleansing and the treatment of gastrointestinal disorders
WO2017160938A1 (en) * 2016-03-15 2017-09-21 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH α8β1 INTEGRIN
CN107929718A (en) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 1 analogs of GLP and GC C receptor stimulating agent composition sustained-release preparations and preparation method thereof
WO2020082168A1 (en) * 2018-10-23 2020-04-30 Abk Biomedical Incorporated Delivery device
CN109467606A (en) * 2018-11-15 2019-03-15 大连理工大学 A kind of Escherichia coli enterotoxin STa-LTB-STb fusion protein and its encoding gene and application
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
RU2712761C1 (en) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Agent for pulmonary endothelial regeneration stimulation at metabolic syndrome combined with chronic obstructive pulmonary disease
CN111265653B (en) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 Application of atrial natriuretic peptide in preparation of medicines for treating inflammatory bowel disease
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
EP4469468A1 (en) 2022-01-28 2024-12-04 Fresenius Kabi iPSUM S.r.l. Process for the preparation of linaclotide
WO2025207484A1 (en) * 2024-03-25 2025-10-02 Merveille.Ai Use of aprepitant and cyclic dipeptide for weight control

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73628A (en) * 1868-01-21 mitchell
US232013A (en) * 1880-09-07 Henry h
US266989A (en) * 1882-11-07 Automatic fire
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US258687A (en) * 1882-05-30 Grain-binder
US32684A (en) * 1861-07-02 Stump-extkactob
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (en) 1987-02-05 1990-03-14 Rotta Research Lab OPTICALLY ACTIVE DERIVATIVES OF ACID 5 PENTILAMINE 5 OXO PENTANOIC R WITH ANTAGONIST ACTIVITY OF THE CHOLECISTOKININ AND PROCEDURE FOR THEIR PREPARATION
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (en) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (en) 1991-04-02 1994-12-23 Logeais Labor Jacques NOVEL N-CYCLOHEXYL BENZAMIDES OR THIOBENZAMIDES DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS.
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
ATE165977T1 (en) 1991-12-30 1998-05-15 Neurex Corp METHODS OF PRODUCING ANALGESIA AND ENHANCEMENT OPIATE ANALGESIA
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JPH08505395A (en) 1993-01-06 1996-06-11 キナートン リミティド Ionic molecule conjugates of biodegradable polyesters and bioactive polypeptides
US5395490A (en) 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
ES2216004T3 (en) * 1993-10-26 2004-10-16 Thomas Jefferson University COMPOSITIONS THAT SPECIFICALLY JOIN COLORECTAL CANCER CELLS AND PROCEDURES FOR THE SAME USE.
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
ES2194998T3 (en) 1995-06-27 2003-12-01 Elan Pharm Inc COMPOSITIONS AND FORMULATIONS TO PRODUCE ANALGESIA AND TO INHIBIT THE PROGRESSION OF NEUROPATHIC PAIN DISORDERS.
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
DE69634416T2 (en) 1995-11-24 2005-12-29 Glaxosmithkline S.P.A. QUINOLINE DERIVATIVES
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
JP3155013B2 (en) 1996-04-23 2001-04-09 キナートン・リミテッド Acid polylactic acid polymer
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DK0975347T3 (en) 1997-02-28 2008-06-16 Nycomed Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclist agonists
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ATE273996T1 (en) 1997-09-12 2004-09-15 Pharis Biotec Gmbh COMPOSITION FOR THE THERAPY OF DIABETES MELLITUS AND OBESITY
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (en) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl COMPOSITIONS INCLUDING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID FOR THE PREPARATION OF SUBCUTANEOUS IMPLANTS HAVING A PROLONGED
WO2001000221A2 (en) 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
ES2209948T3 (en) 1999-08-18 2004-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. FORMULATION OF A SUSTAINED LIBERATION PEPTICO.
SE9903291D0 (en) 1999-09-15 1999-09-15 Astra Ab New process
WO2001025266A1 (en) 1999-10-06 2001-04-12 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
PT1225897E (en) 1999-11-01 2005-01-31 John Rhodes COMPOSITION FOR THE TREATMENT OF OBSTIPACY AND IRRITAVEL INTESTINAL SYNDROME
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
EP1216707B1 (en) 2000-12-22 2005-02-09 Institut Pasteur Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
JP4206272B2 (en) * 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド Guanylate cyclase receptor agonists for treating tissue inflammation and carcinogenesis
EP1451211A2 (en) 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
AU2002316771A1 (en) 2001-06-05 2002-12-16 Yalcin Cetin Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
FR2830451B1 (en) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med USE OF THYMULIN-LIKE PEPTIDES (PAT) FOR THE MANUFACTURE OF PAIN MEDICATIONS
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
CA2479350A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CN100411618C (en) 2002-05-17 2008-08-20 迪欧加药品公司 Use of compounds that are potent selective opioid receptor modulators
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (en) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson USE OF GCC LIGANDS
WO2007022531A2 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
SG168407A1 (en) 2011-02-28
WO2004069165A3 (en) 2005-03-17
HUS1300022I1 (en) 2019-11-28
EP1594517A2 (en) 2005-11-16
DK1594517T3 (en) 2007-10-29
RU2014153593A (en) 2016-07-20
PT1594517E (en) 2007-07-20
NO20130460L (en) 2005-10-26
CA2514507C (en) 2012-03-20
ES2350123T3 (en) 2011-01-18
AU2009235993A1 (en) 2009-11-26
SG192300A1 (en) 2013-08-30
NZ541595A (en) 2008-08-29
CA2514507A1 (en) 2004-08-19
CY1113217T1 (en) 2016-04-13
EP2246360A1 (en) 2010-11-03
BRPI0407071B8 (en) 2021-05-25
CY2013022I1 (en) 2020-05-29
JP5563384B2 (en) 2014-07-30
JP4584911B2 (en) 2010-11-24
EP1911763A2 (en) 2008-04-16
CY2013021I2 (en) 2025-07-04
NO336768B1 (en) 2015-11-02
JP2013116910A (en) 2013-06-13
US20110124583A1 (en) 2011-05-26
RU2005127058A (en) 2006-03-10
EP1911763A3 (en) 2008-06-25
AU2004210161B2 (en) 2009-11-26
HK1078768A1 (en) 2006-03-24
NO20053864L (en) 2005-10-26
NZ570134A (en) 2010-02-26
IL169863A (en) 2012-10-31
DK1911763T3 (en) 2010-11-15
NO2014013I2 (en) 2014-05-21
AU2009235993B2 (en) 2013-07-04
WO2004069165A2 (en) 2004-08-19
NO2014013I1 (en) 2014-06-02
PT1911763E (en) 2010-11-18
US7704947B2 (en) 2010-04-27
US20090005534A1 (en) 2009-01-01
US8080526B2 (en) 2011-12-20
EP1594517A4 (en) 2006-03-29
SI1911763T1 (en) 2010-11-30
US20040266989A1 (en) 2004-12-30
JP2006516631A (en) 2006-07-06
DE602004007105D1 (en) 2007-08-02
BR122018074353B1 (en) 2019-07-16
RU2008147983A (en) 2010-06-10
IL221380A0 (en) 2012-09-24
CN101787073A (en) 2010-07-28
RU2763796C2 (en) 2022-01-11
CN1795007A (en) 2006-06-28
CY1110905T1 (en) 2015-06-10
NL300593I2 (en) 2020-04-15
KR20050106404A (en) 2005-11-09
EP1911763B1 (en) 2010-08-11
MXPA05008097A (en) 2006-02-08
BRPI0407071B1 (en) 2019-02-12
LU92201I2 (en) 2013-11-22
ES2285417T3 (en) 2007-11-16
FR13C0029I1 (en) 2013-07-05
JP5748791B2 (en) 2015-07-15
LU92200I2 (en) 2024-03-21
KR101227627B1 (en) 2013-01-31
ES2387848T3 (en) 2012-10-02
EP2246360B1 (en) 2012-06-27
SI1594517T1 (en) 2007-10-31
RU2353383C2 (en) 2009-04-27
EP1594517B1 (en) 2007-06-20
NO334112B1 (en) 2013-12-09
JP2010222377A (en) 2010-10-07
ATE365174T1 (en) 2007-07-15
LU92200I1 (en) 2020-06-02
SI2246360T1 (en) 2012-10-30
ATE477268T1 (en) 2010-08-15
KR101227626B1 (en) 2013-02-01
DE602004007105T2 (en) 2008-02-28
DK2246360T3 (en) 2012-08-13
NO20053864D0 (en) 2005-08-18
CN101787073B (en) 2013-12-25
LTC1594517I2 (en) 2020-03-10
KR20110114682A (en) 2011-10-19
DE602004028678D1 (en) 2010-09-23
CY2013021I1 (en) 2020-05-29
NL300593I1 (en) 2015-10-21
PT2246360E (en) 2012-08-31
FR13C0030I1 (en) 2013-07-05
RU2014153593A3 (en) 2018-08-06
BRPI0407071A (en) 2006-01-24
FR13C0029I2 (en) 2024-04-19
CN100589839C (en) 2010-02-17
BR122018074353B8 (en) 2023-05-02
AU2004210161A1 (en) 2004-08-19
CY1111058T1 (en) 2015-06-11
RU2543350C2 (en) 2015-02-27

Similar Documents

Publication Publication Date Title
HUS1300022I1 (en) Compositions for the treatment of gastrointestinal disorders
SG153824A1 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005016244A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006086653A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007101158A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2008002971A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
MX386452B (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
WO2004093908A3 (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2005074575A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2002095396A3 (en) In line test device and methods of use
WO2007062168A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006102069A3 (en) Methods and compositions for the treatment of hypertension and gastrointestinal disorders
Mobberley Restoring Baird's image